NASDAQ:INCR InterCure (INCR) Stock Price, News & Analysis $1.56 +0.04 (+2.29%) Closing price 03:57 PM EasternExtended Trading$1.54 -0.02 (-1.60%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About InterCure Stock (NASDAQ:INCR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get InterCure alerts:Sign Up Key Stats Today's Range$1.53▼$1.6050-Day Range$1.22▼$1.6052-Week Range$1.17▼$3.28Volume11,574 shsAverage Volume28,599 shsMarket Capitalization$71.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewInterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Read More… InterCure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreINCR MarketRank™: InterCure scored higher than 8% of companies evaluated by MarketBeat, and ranked 914th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for InterCure. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioInterCure has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.05% of the float of InterCure has been sold short.Short Interest Ratio / Days to CoverInterCure has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InterCure has recently increased by 21.50%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInterCure does not currently pay a dividend.Dividend GrowthInterCure does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.05% of the float of InterCure has been sold short.Short Interest Ratio / Days to CoverInterCure has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InterCure has recently increased by 21.50%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.44 News SentimentInterCure has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for InterCure this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, InterCure insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.24% of the stock of InterCure is held by insiders.Percentage Held by InstitutionsOnly 8.34% of the stock of InterCure is held by institutions.Read more about InterCure's insider trading history. Receive INCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InterCure and its competitors with MarketBeat's FREE daily newsletter. Email Address INCR Stock News HeadlinesInterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025May 1, 2025 | prnewswire.comInterCure names Alexander Rabinovich as Chairman, replacing Ehud BarakFebruary 15, 2025 | markets.businessinsider.comIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.May 29, 2025 | Colonial Metals (Ad)InterCure Names Alexander Rabinovich as Chairman Replacing Ehud BarakFebruary 12, 2025 | prnewswire.comInterCure Secures Major Funding to Boost GrowthDecember 22, 2024 | markets.businessinsider.comInterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz FacilityDecember 20, 2024 | prnewswire.comRising High: Exclusive talk with house of brands Carma HoldCoNovember 7, 2024 | markets.businessinsider.comInterCure Ltd. (INCR)October 16, 2024 | finance.yahoo.comSee More Headlines INCR Stock Analysis - Frequently Asked Questions How have INCR shares performed this year? InterCure's stock was trading at $1.59 at the beginning of the year. Since then, INCR stock has increased by 1.3% and is now trading at $1.61. View the best growth stocks for 2025 here. How do I buy shares of InterCure? Shares of INCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of InterCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that InterCure investors own include NVIDIA (NVDA), Meta Platforms (META), PayPal (PYPL), Advanced Micro Devices (AMD), Tesla (TSLA), Innovative Industrial Properties (IIPR) and AbbVie (ABBV). Company Calendar Today5/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INCR CIK1857030 Webwww.intercure.co Phone972774605012FaxN/AEmployees350Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.15 Current Ratio1.78 Quick Ratio1.15 Sales & Book Value Annual Sales$238.85 million Price / Sales0.29 Cash FlowN/A Price / Cash FlowN/A Book Value$2.72 per share Price / Book0.57Miscellaneous Outstanding Shares45,573,000Free Float45,464,000Market Cap$70.41 million OptionableOptionable Beta1.25 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:INCR) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InterCure Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share InterCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.